Physician profile
Donald Robinson
NPI 1215907159
$444.62
in general payments reported to CMS, 2019-2025
12 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.13 · 2022: $63.83 · 2023: $115 · 2024: $13.90 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $96.97 | 2023-2024 | Vraylar |
| Vanda Pharmaceuticals INC. | $59.73 | 2025 | Fanapt |
| Amgen INC. | $57.92 | 2025 | Krystexxa, Otezla, Repatha |
| Exact Sciences Corporation | $41.08 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $39.14 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.68 | 2023-2025 | Caplyta |
| Avanir Pharmaceuticals, INC. | $24.12 | 2022 | |
| Novo Nordisk INC | $21.69 | 2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $21.37 | 2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $19.86 | 2025 | Uzedy |
| Biohaven Pharmaceutical Holding Company LTD. | $16.93 | 2022 | |
| Glaxosmithkline, LLC. | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.